Head-To-Head Survey: Oncobiologics (NASDAQ:OTLK) versus Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Xenetic Biosciences and Oncobiologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26 million	1.40	-$2.68 million	($1.16)	-1.72
Oncobiologics	$1.35 million	88.04	-$62.42 million	($0.77)	-0.63

Xenetic Biosciences has higher revenue and earnings than Oncobiologics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Xenetic Biosciences and Oncobiologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
Oncobiologics	1	2	2	0	2.20

Oncobiologics has a consensus target price of $5.20, indicating a potential upside of 965.14%. Given Oncobiologics’ stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than Xenetic Biosciences.

Risk & Volatility

Xenetic Biosciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Xenetic Biosciences and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.